Tenon Medical Announces Issuance of Three Notices of Allowance for Patent Applications from the USPTO
Tenon Medical (NASDAQ:TNON) has announced the issuance of three Notices of Allowance from the USPTO for patent applications related to their Catamaran® SI Joint Fusion System. Two applications focus on unique drug delivery compositions for bone growth, while the third addresses correcting failed SI joint stabilization without removing the failed implant.
These additions will expand Tenon's patent portfolio to 9 granted patents and 26 pending applications worldwide. Richard Ginn, Co-Founder and CTO, emphasized the importance of intellectual property protection in their growth strategy and commitment to innovation in SI joint treatment.
Tenon Medical (NASDAQ:TNON) ha annunciato l'emissione di tre Avvisi di Concessione dall'USPTO per le domande di brevetto relative al loro Catamaran® SI Joint Fusion System. Due domande si concentrano su composizioni uniche per la somministrazione di farmaci per la crescita ossea, mentre la terza tratta la correzione della stabilizzazione fallita dell'articolazione sacroiliaca senza rimuovere l'impianto fallito.
Queste aggiunte espanderanno il portafoglio brevetti di Tenon a 9 brevetti concessi e 26 domande pendenti in tutto il mondo. Richard Ginn, Co-Fondatore e CTO, ha sottolineato l'importanza della protezione della proprietà intellettuale nella loro strategia di crescita e l'impegno per l'innovazione nel trattamento dell'articolazione sacroiliaca.
Tenon Medical (NASDAQ:TNON) ha anunciado la emisión de tres Avisos de Concesión de la USPTO para las solicitudes de patentes relacionadas con su Catamaran® SI Joint Fusion System. Dos solicitudes se centran en composiciones únicas de entrega de medicamentos para el crecimiento óseo, mientras que la tercera aborda la corrección de la estabilización fallida de la articulación sacroilíaca sin retirar el implante fallido.
Estas adiciones expandirán el portafolio de patentes de Tenon a 9 patentes otorgadas y 26 solicitudes pendientes en todo el mundo. Richard Ginn, Co-Fundador y CTO, enfatizó la importancia de la protección de la propiedad intelectual en su estrategia de crecimiento y su compromiso con la innovación en el tratamiento de la articulación sacroilíaca.
테논 메디컬 (NASDAQ:TNON)은 세 건의 허가 통지서를 USPTO에서 발표하였으며, 이는 그들의 카타마란® SI 관절 융합 시스템과 관련된 특허 신청입니다. 두 건의 신청은 뼈 성장을 위한 독특한 약물 전달 조성물에 초점을 맞추고 있으며, 세 번째 신청은 실패한 임플란트를 제거하지 않고 실패한 SI 관절 고정을 수정하는 것을 다룹니다.
이 추가로 인해 테논은 전 세계적으로 9개의 등록된 특허와 26개의 대기 중인 신청서를 보유하게 됩니다. 리차드 긴, 공동 창립자이자 CTO는 지적 재산권 보호의 중요성을 강조하며, SI 관절 치료에 대한 혁신과 성장 전략의 일환으로 이를 강조했습니다.
Tenon Medical (NASDAQ:TNON) a annoncé l'émission de trois Avis de Concession de l'USPTO concernant des demandes de brevet relatives à leur Système de Fusion des Articulations SI Catamaran®. Deux demandes se concentrent sur des compositions uniques de délivrance de médicaments pour la croissance osseuse, tandis que la troisième traite de la correction de la stabilisation échouée de l'articulation si sans retirer l'implant défaillant.
Ces ajouts permettront d'étendre le portefeuille de brevets de Tenon à 9 brevets accordés et 26 demandes en attente dans le monde entier. Richard Ginn, co-fondateur et CTO, a souligné l'importance de la protection de la propriété intellectuelle dans leur stratégie de croissance et leur engagement envers l'innovation dans le traitement des articulations SI.
Tenon Medical (NASDAQ:TNON) hat die Erteilung von drei Zulassungsmitteilungen vom USPTO für Patent-Anmeldungen im Zusammenhang mit ihrem Catamaran® SI Joint Fusion System bekannt gegeben. Zwei Anmeldungen konzentrieren sich auf einzigartige Medikamente zur Knochenbildung, während die dritte die Korrektur einer fehlgeschlagenen SI-Gelenkstabilisierung ohne Entfernen des fehlgeschlagenen Implantats behandelt.
Diese Ergänzungen werden das Patentportfolio von Tenon auf 9 erteilte Patente und 26 ausstehende Anmeldungen weltweit erweitern. Richard Ginn, Mitgründer und CTO, betonte die Bedeutung des Schutzes geistigen Eigentums in ihrer Wachstumsstrategie und das Engagement für Innovationen in der SI-Gelenkbehandlung.
- Received three Notices of Allowance for new patents from USPTO
- Expanding patent portfolio to 9 granted patents and 26 pending applications
- New patents cover unique drug delivery compositions and failed implant correction
- Strengthening competitive position in the SI joint treatment industry
- None.
The issuance of three Notices of Allowance from the USPTO for Tenon Medical's patent applications is a positive development for the company's intellectual property strategy. These patents, focusing on drug delivery compositions and unique configurations for failed SI joint stabilization, demonstrate Tenon's commitment to innovation in the field of Sacroiliac Joint disorders.
The expansion of Tenon's patent portfolio to 9 granted patents and 26 pending applications worldwide strengthens their market position and potential competitive advantage. This robust IP protection could deter competitors and increase the company's valuation. However, investors should note that while patents are valuable assets, they don't guarantee market success or revenue growth. The commercial viability of these innovations and Tenon's ability to monetize their IP will be important factors to monitor.
Tenon Medical's patent developments signal a strategic focus on the Sacroiliac Joint (SIJ) fusion market, a niche but growing segment in orthopedics. The company's emphasis on less invasive approaches and solutions for failed implants aligns with current trends in orthopedic surgery towards minimally invasive procedures and revision surgeries.
However, the SIJ fusion market is becoming increasingly competitive, with several established players. Tenon's success will depend on their ability to differentiate their Catamaran® system and gain market share. While the expanded patent portfolio provides a strong foundation, investors should closely monitor Tenon's clinical outcomes, surgeon adoption rates and revenue growth to assess the real-world impact of these innovations on the company's market position.
Tenon Now Holds 9 Granted Patents and 26 Pending Applications for the Catamaran® SI Joint Fusion System Worldwide
LOS GATOS, CA / ACCESSWIRE / September 19, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced the United States Patent and Trademark Office ("USPTO") issued three (3) Notices of Allowance for U.S. Patent Application Numbers 17,469,132 and 17/468,811, both entitled "Sacroiliac Joint Stabilization Prostheses", and 18/612,032, entitled "Systems, Apparatus and Methods for Stabilizing Sacroiliac Joints". The U.S. patents based on the applications should thus issue within the next ninety (90) days.
U.S. Pat. App. Nos. 17,469,132 and 17/468,811 are directed to SI joint prostheses that include unique drug delivery compositions that aid in bone growth about and within the prostheses when implanted in a SI joint. U.S. Pat. App. No. 18/612,032 is directed to SI joint prostheses with unique configurations to correct failed SI joint stabilization with alternative commercial SI joint implants without requiring removal of the failed implant.
The three (3) U.S. patents, when issued, will further enhance the Company's growing patent portfolio for its Catamaran® SI Joint implant system, which now comprises nine (9) issued U.S. and foreign (International) patents, and twenty-six (26) pending U.S. and foreign patent applications.
"A critical component of our growth strategy is pursuing and obtaining effective intellectual property protection for the key technology, processes and devices of our Catamaran® SI Joint Fusion System. As we advance our commercialization efforts, we are pleased to have reinforcement by the USPTO, which has again provided us with Notice of Allowances for these three new patents," said Richard Ginn, Co-Founder and Chief Technology Officer of Tenon Medical. "As we continue to aggressively develop our intellectual property, we have added a number of new patents and patent applications, including the three (3) soon to be issued U.S. patents and three (3) recently filed U.S. patent applications. IP efforts such as these serve to further solidify our international patent portfolio, protect our technology platform, strengthen our competitive position in the industry, and underscore our commitment to innovation in advancing a less invasive approach to the SI joint."
About Tenon Medical, Inc.
Tenon Medical, Inc., a medical device company formed in 2012, has developed The Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran™ Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Since the national launch of the Catamaran SI Joint Fusion System in October 2022 Tenon is focused on two commercial opportunities with its System in the SI Joint market which includes: 1) Primary SI Joint procedures, and 2) Revision procedures of failed SI Joint implants. For more information, please visit www.tenonmed.com.
The Tenon Medical logo Tenon Medical, and Catamaran are registered trademarks of Tenon Medical, Inc. MAINSAIL is a trademark of Tenon Medical
Safe Harbor
This press release contains "forward-looking statements," which are statements related to events, results, activities, or developments that Tenon expects, believes, or anticipates will or may occur in the future. Forward-looking often contains words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," "aims," and similar expressions and the negative versions thereof. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, please review our Annual Report on 10-K on file with the Securities and Exchange Commission at www.sec.gov, particularly the information contained in the section entitled "Risk Factors". We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.
IR Contact:
Shannon Devine / Rory Rumore
203-741-8811
MZ North America
tenon@mzgroup.us
SOURCE: Tenon Medical, Inc.
View the original press release on accesswire.com
FAQ
What new patents did Tenon Medical (TNON) receive allowance for?
How many patents does Tenon Medical (TNON) now hold for its Catamaran SI Joint Fusion System?
What are the key features of Tenon Medical's (TNON) new patent applications?
How does Tenon Medical (TNON) view the importance of these new patents?
